Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study.
Arnon P KaterJenny Qun WuThomas J KippsBarbara EichhorstPeter HillmenJames D'RozarioSarit E AssoulineCarolyn OwenTadeusz RobakJavier de laSernaUlrich JaegerGuillaume CartronMarco MontilloJulie DuboisEric ElderingClemens MellinkAnne-Marie F van der Kevie-KersemaekersSu Young KimBrenda ChylaElizabeth PunnooseChristopher R BolenZoe June AssafYanwen JiangJue WangMarcus LefebureMichelle BoyerKathryn HumphreyJohn Francis SeymourPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020)
Efficacy benefits with fixed-duration VenR are sustained and particularly durable in patients who achieve uMRD. Salvage therapy with ibrutinib after VenR achieved high response rates. Genetic mutations and GC affected MRD rates and PFS.
Keyphrases
- chronic lymphocytic leukemia
- phase iii
- open label
- clinical trial
- copy number
- diffuse large b cell lymphoma
- acute lymphoblastic leukemia
- acute myeloid leukemia
- double blind
- phase ii
- genome wide
- multiple myeloma
- hodgkin lymphoma
- placebo controlled
- gene expression
- high resolution
- mass spectrometry
- bone marrow
- dna methylation
- gas chromatography
- smoking cessation